Skip to main content Back to Top


Deferoxamine Injection

Products Affected - Description

    • Deferoxamine injection, Alvogen, 2 gram, vial, 1 count, NDC 47781-0624-07
    • Deferoxamine injection, Alvogen, 500 mg, vial, 1 count, NDC 47781-0623-07 - discontinued

Reason for the Shortage

    • Fresenius Kabi had deferoxamine on shortage due to increased demand.
    • Pfizer had deferoxamine on shortage due to manufacturing delays.
    • Novartis has Desferal available.
    • Alvogen did not provide a reason for the shortage. Alvogen discontinued the 500 mg vials in late-2019.
    • Apo-Pharma launched deferoxamine injection in mid-2018.

Available Products

    • Desferal injection, Novartis, 500 mg, vial, 4 count, NDC 00078-0467-91
    • Deferoxamine injection, Apo-Pharma, 2 gram, vial, 4 count, NDC 52609-4504-06
    • Deferoxamine injection, Apo-Pharma, 500 mg, vial, 4 count, NDC 52609-4505-06
    • Deferoxamine injection, Fresenius Kabi, 2 gram, vial, 1 count, NDC 63323-0599-30
    • Deferoxamine injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0597-10
    • Deferoxamine injection, Pfizer, 2 gram, vial, 4 count, NDC 00409-2337-25
    • Deferoxamine injection, Pfizer, 500 mg, vial, 4 count, NDC 00409-2336-10

Estimated Resupply Dates

    • Alvogen has short-dated deferoxamine 2 gram vials available with an expiration date of June 2020.


Updated March 13, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created February 7, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.


Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.